Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-12-12
|
UCART19 |
relapsed or refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) |
1 |
Cellectis (France) Servier (France) Pfizer (USA - NY) |
Cancer - Oncology |
2017-12-12
|
TPIV200 |
prevention of cancer recurrence in women with triple-negative breast cancer (TNBC) who have completed first-line surgery and radiotherapy/chemotherapy |
2 |
Tapimmune (USA - FL) |
Cancer - Oncology |
2017-12-12
|
Tesomet® (tesofensine and metoprolol) |
type 2 diabetes |
2a |
Saniona (Denmark) |
Metabolic diseases |
2017-12-12
|
JCAR017 (lisocabtagene maraleucel) |
relapsed/refractory B cell non-Hodgkin lymphoma (NHL) |
1 |
Juno Therapeutics (USA - WA) |
Cancer - Oncology |
2017-12-12
|
IFN alpha Kinoid |
type 1 diabetes |
preclinical |
Neovacs (France) |
Autoimmune diseases - Metabolic diseases |
2017-12-12
|
caplacizumab |
thrombotic thrombocytopenic purpura (TTP) |
3 |
Ablynx (Belgium) |
Autoimmune diseases - Rare diseases |
2017-12-12
|
UCART19 |
relapsed/refractory B acute lymphoblastic leukaemia (ALL) |
1 |
Cellectis (France) Servier (France) Pfizer (USA - NY) |
Cancer - Oncology |
2017-12-11
|
axicabtagene ciloleucel (KTE-C19) (autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor) |
acute lymphoblastic leukemia (ALL) |
1-2 |
Kite Pharma (USA - CA) |
Cancer - Oncology |
2017-12-11
|
crizanlizumab (SEG101) |
sickle cell disease |
2 |
Novartis (Switzerland) |
Cancer - Oncology |
2017-12-11
|
SPK-9001 |
hemophilia B |
1-2 |
Pfizer (USA - NY) Spark Therapeutics (USA - PA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-11
|
BCT-197 (acumapimod) |
acute exacerbations of chronic obstructive pulmonary disease |
2b |
Mereo Biopharma (UK) |
Infectious diseases - Respiratory diseases |
2017-12-11
|
LentiGlobin® BB305 (autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) |
beta-thalassemia, sickle cell disease |
1-2 |
bluebird bio (USA - MA) |
Hematologic diseases - Genetic diseases - Rare diseases |
2017-12-11
|
Adcetris® (brentuximab vedotin) and Opdivo® (nivolumab) |
relapsed or refractory classical Hodgkin lymphoma |
1-2 |
BMS (USA - NY) Seattle Genetics (USA - WA) |
Cancer - Oncology |
2017-12-11
|
FP-1201-lyo (the lyophilised form of Traumakine® (human recombinant interferon-beta 1a) |
acute respiratory distress syndrome (ARDS) |
3 |
Faron Pharmaceuticals (Finland) |
Lung diseases - Respiratory diseases - Rare diseases |
2017-12-11
|
WVE-3972-01 |
amyotrophic lateral sclerosis (ALS) frontotemporal dementia (FTD) |
preclinical |
Wave LIfe Sciences (USA - MA) |
Rare diseases - Genetic diseases - Neurological diseases - Neurodegenerative diseases |
2017-12-11
|
CAEL-101 (mAb 11-1F4) |
amyloid light chain amyloidosis |
1b |
Caelum Biosciences (USA - NY) |
Rare diseases - Genetic diseases |
2017-12-11
|
FT500 |
|
preclinical |
Fate Therapeutics (USA - CA) |
Cancer - Oncology |
2017-12-11
|
EZM8266 |
sickle cell disease (SCD) |
preclinical |
Epizyme (USA - MA) |
Rare diseases - Genetic diseases - Hematological diseases |
2017-12-10
|
polatuzumab vedotin |
people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. |
1b-2 |
Roche (Switzerland) |
Cancer - Oncology |
2017-12-10
|
CTX001 |
Beta-thalassemia, sickle cell disease |
preclinical |
Crispr Therapeutics (Switzerland - UK) |
Rare diseases - Genetic diseases - Hematological diseases |